Ipilimumab
Other Monoclonal Antibodies and Antibody Drug Conjugates
Sold as Yervoy
- Drug class
- Other Monoclonal Antibodies and Antibody Drug Conjugates
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 7
Overview
Ipilimumab is an active pharmaceutical ingredient in the Other Monoclonal Antibodies and Antibody Drug Conjugates group (L01FX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 5 | May 15, 2026 |
| EU European Union | EMA | 1 | November 21, 2025 |
| CA Canada | Health Canada | 1 | November 14, 2025 |
GBUnited Kingdom· MHRA
5 products
Uses
4). 1). 1). Non-small cell lung cancer (NSCLC) YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
Malignant pleural mesothelioma (MPM) YERVOY in combination with nivolumab is indicated for the first line treatment of adult patients with unresectable malignant pleural mesothelioma. 1). Oesophageal squamous cell carcinoma (OSCC) YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.
Hepatocellular carcinoma (HCC) YERVOY in combination with nivolumab is indicated for the first line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
EUEuropean Union· EMA
1 product
Uses
4). 1). 1). Non-small cell lung cancer (NSCLC) YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
3 Malignant pleural mesothelioma (MPM) YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. 1). Oesophageal squamous cell carcinoma (OSCC) YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.
Hepatocellular carcinoma (HCC) YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
CACanada· Health Canada
1 product
Uses
5 Missed Dose 03/2022 7 WARNINGS AND PRECAUTIONS TBD TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ............................................................................................. 4 TABLE OF CONTENTS .............................................................................................................
4 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................ 6 1 INDICATIONS......................................................................................................................
1 Pediatrics ............................................................................................................. 2 Geriatrics .............................................................................................................
7 2 CONTRAINDICATIONS ......................................................................................................... 7 3 SERIOUS WARNINGS AND PRECAUTIONS BOX........................................................................
Drug interactions
Known interactions involving Ipilimumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB151050151 · revised May 1, 2026
- [2]European Medicines Agency · EMEA/H/C/002213 · revised November 21, 2025
- [3]Health Canada (DPD) · 02379384 · revised November 14, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.